Literature DB >> 33584499

Case Report: Posterior Reversible Leukoencephalopathy Syndrome (PRES) as a Biologically Predictable Neurological Association in Severe COVID-19. First Reported Case From Australia and Review of Internationally Published Cases.

Tissa Wijeratne1,2,3, Chanith Wijeratne2,4, Leila Karimi1,2, Carmela Sales2, Sheila Gillard Crewther1,2.   

Abstract

Reports of different types of neurological manifestations of COVID-19 are rapidly increasing, including changes of posterior reversible leukoencephalopathy syndrome (PRES). Here we describe the first reported case of COVID-19 and PRES in Australia diagnosed on basis of MRI brain imaging and confirmed clinically by presence of confusion, delirium, headaches, also associated with hypertension and blood pressure variability and stable long-term kidney problems. He made full recovery as his blood pressure was controlled and clinical status was supported with appropriate supportive therapy. Although traditionally a rare condition, PRES is likely to be more common among patients with COVID-19 pathobiology there is Renin downregulation of ACE2 receptors, involvement of Renin-Angiotensin-Aldosterone system, endotheliitis, cytokine storm, and hyper-immune response. Thus we advocate clinical suspicion and early brain imaging with MRI brain among vulnerable patients with known co-morbidities, and diagnosed with COVID-19 given that hypertension and blood pressure variability are often exacerbated by acute SARS-CoV-2 immune reactions. Such acute hypertensive encephalopathy was able to be reversed with timely supportive therapy ensuring re-hydration and re-establishment of blood pressure control.
Copyright © 2021 Wijeratne, Wijeratne, Karimi, Sales and Crewther.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; case report; hypertension; posterior reversible encephalopathy syndrome (PRES)

Year:  2021        PMID: 33584499      PMCID: PMC7875083          DOI: 10.3389/fneur.2020.600544

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  31 in total

Review 1.  Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions.

Authors:  Jennifer E Fugate; Alejandro A Rabinstein
Journal:  Lancet Neurol       Date:  2015-07-13       Impact factor: 44.182

2.  Posterior reversible encephalopathy syndrome in liver transplant patients: clinical presentation, risk factors and initial management.

Authors:  R J Cruz; A DiMartini; M Akhavanheidari; N Iacovoni; J F Boardman; J Donaldson; A Humar; W S Bartynski
Journal:  Am J Transplant       Date:  2012-04-11       Impact factor: 8.086

3.  Imaging pattern of intracranial hemorrhage in the setting of posterior reversible encephalopathy syndrome.

Authors:  Aseem Sharma; Ryan T Whitesell; Kelsey J Moran
Journal:  Neuroradiology       Date:  2009-12-03       Impact factor: 2.804

4.  COVID-19-Associated PRES-like Encephalopathy with Perivascular Gadolinium Enhancement.

Authors:  G Conte; S Avignone; M Carbonara; M Meneri; F Ortolano; C Cinnante; F Triulzi
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-13       Impact factor: 3.825

5.  Early postmortem brain MRI findings in COVID-19 non-survivors.

Authors:  Tim Coolen; Valentina Lolli; Niloufar Sadeghi; Antonin Rovai; Nicola Trotta; Fabio Silvio Taccone; Jacques Creteur; Sophie Henrard; Jean-Christophe Goffard; Olivier Dewitte; Gilles Naeije; Serge Goldman; Xavier De Tiège
Journal:  Neurology       Date:  2020-06-16       Impact factor: 9.910

6.  Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19.

Authors:  Louis Kishfy; Marcel Casasola; Peymaan Banankhah; Arshi Parvez; Yu Jen Jan; Anant M Shenoy; Carey Thomson; Mahmoud A AbdelRazek
Journal:  J Neurol Sci       Date:  2020-05-23       Impact factor: 3.181

7.  Rare presentations of COVID-19: PRES-like leukoencephalopathy and carotid thrombosis.

Authors:  Florence X Doo; Gassan Kassim; Daniel R Lefton; Shanna Patterson; Hien Pham; Puneet Belani
Journal:  Clin Imaging       Date:  2020-07-16       Impact factor: 1.605

8.  Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient.

Authors:  Sara Gómez-Enjuto; Virgilio Hernando-Requejo; José Lapeña-Motilva; Gonzalo Ogando-Durán; Daniel Fouz-Ruiz; Julio Domingo-García; Elena Rodríguez-García; Carlos Alberto Cemillán-Fernández
Journal:  Seizure       Date:  2020-06-06       Impact factor: 3.184

Review 9.  Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration.

Authors:  Jose L Labandeira-Garcia; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Jannette Rodriguez-Pallares; Jose L Lanciego; Maria J Guerra
Journal:  Front Aging Neurosci       Date:  2017-05-03       Impact factor: 5.750

Review 10.  Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.

Authors:  Hao Cheng; Yan Wang; Gui-Qiang Wang
Journal:  J Med Virol       Date:  2020-04-05       Impact factor: 2.327

View more
  3 in total

1.  Posterior reversible encephalopathy syndrome - A pathology that should not be overlooked in the era of COVID-19.

Authors:  Patricia Ioan; Athena Cristina Ribigan; Octaviana Rusu; Ionut Flavius Bratu; Raluca Stefania Badea; Florina Antochi
Journal:  Am J Emerg Med       Date:  2022-03-13       Impact factor: 4.093

2.  Asymmetric posterior reversible encephalopathy syndrome secondary to epilepsy occurring in the chronic phase of subarachnoid hemorrhage.

Authors:  Atsushi Matsumoto; Hiroaki Hanayama; Hiroaki Matsumoto; Yusuke Tomogane; Hiroaki Minami; Atsushi Masuda; Ikuya Yamaura; Yutaka Hirata; Yasuhisa Yoshida
Journal:  Surg Neurol Int       Date:  2022-04-08

3.  Neurological Manifestations in a Cohort of Egyptian Patients with COVID-19: A Prospective, Multicenter, Observational Study.

Authors:  Doaa A Mekkawy; Sherif Hamdy; Maged Abdel-Naseer; Hatem S Shehata; Ahmed Al Halfawy; Nevin M Shalaby; Ghaydaa A Shehata; Anwar M Ali; Alaa Elmazny; Sandra M Ahmed; Jumana H Ismail; Aml Ibraheim; Hoda M Abdel-Hamid; Rehab Magdy; Younan Kabara Ayoub; Ahmed E Taha; Nahla Merghany; Nourhan M Soliman; Haidy Elshebawy; Samar E S Abdelal; Lobna El-Ghoneimy; Aussan Al-Athwari; Nirmeen A Kishk; Mona A F Nada; Marwa Farghaly; Amr Hassan; Mohamed I Hegazy; Ahmed Abdelalim; Husam S Mourad; Amira Hassouna; Alshimaa S Othman; Tissa Wijeratne
Journal:  Brain Sci       Date:  2022-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.